insights_auto
Hvorfor har BMY gått ned? 3,83%?
Gå mer i dybdenchevron_right
BMY:NYSE
Bristol-Myers Squibb Co
58,81 USD
arrow_downward
−3,83%(−2,34) 1 D
58,80 USD
arrow_downward
−0,02% (−0,010)bedtimeEtter stengetid
Stengt: 5. okt., 16:00:05 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for BMY …
Åpne
59,89 USD
Høy
60,15 USD
Lav
58,33 USD
Markedsverdi
120,13 mrd.
Snittvolum
10,43 mill.
Volum
0,00
Utbytte
4,28 %
Kvartalsvis utbytte
0,63 USD
Første dato etter utbytte
2. okt. 2026
P/E-forhold
12,95
52 u høy
68,64 USD
52 u lav
42,52 USD
EPS
4,54 USD
Beta
0,19
Utestående aksjer
2,04 mrd.
Antall ansatte
32k
Åpne
59,89 USD
Høy
60,15 USD
Lav
58,33 USD
Markedsverdi
120,13 mrd.
Snittvolum
10,43 mill.
Volum
0,00
Utbytte
4,28 %
Kvartalsvis utbytte
0,63 USD
Første dato etter utbytte
2. okt. 2026
P/E-forhold
12,95
52 u høy
68,64 USD
52 u lav
42,52 USD
EPS
4,54 USD
Beta
0,19
Utestående aksjer
2,04 mrd.
Antall ansatte
32k
Nyhetssaker
Fra nettkilder og nyhetspartnere
GuruFocus
·
for 1 time siden
Bristol-Myers Squibb Co (BMY) Shares Fall 3.8% -- GF Value Says Still Overvalued
Insider Monkey
·
for 6 timer siden
Bristol Myers (BMY) Stock is Trading Below 10 Times Forward Earnings. Here’s Why it Matters
Investing.com
·
for 7 timer siden
Why is Bristol-Myers Squibb stock sliding today?
News Corp
·
for 8 timer siden
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
Profil
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
Om Bristol-Myers Squibb Co
Administrerende direktørChris Boerner
Ansatte32,5k
Grunnlagt1887
HovedkontorNew York, New York, USA
Sektor-
Nettstedbms.com